Ramírez SK, Rojas MB, Grouille J

Language: Spanish
References: 22
Page: 112-118
PDF size: 728.79 Kb.

ABSTRACT

Cystic fibrosis is a disease that affects predominately the pulmonary parenchyma, predisposing patients to colonization and chronic infection difficult to control. One of the most important agents in this population is atypical mycobacteria. This implies the use of prolonged antibiotic treatment cycles, which leads to higher risk to develop adverse events. Specifically, linezolid presents a series of toxicity mechanisms that have been related to its capacity to cause alteration of the mitochondrial function. We present the case of a male patient of 23 years with cystic fibrosis, who had 3 months history of a chronic infection with Mycobacterium abscessus. He was treated with linezolid for two months, then he presented to the hospital with lactic acidosis, bicitopenia, peripheral neuropathy and hepatitis with a cholestasic pattern. The diagnosis of drug toxicity due to Linezolid was made. linezolid was discontinued and intermittent hemodialysis was performed. The patient had a satisfactory outcome.

REFERENCES

1. Paranjape S Mogayzel P. Cystic Fibrosis. Pediatr Rev. 2014; 35(5): 194-228.

2. Shaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect. 2015; 89: 309-313.

3. Sherrad L Tunney M Elborn S. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014; 384(9944): 703-713.

4. Martiniano S Nick J Daley C. Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Clin Chest Med. 2016; 37: 83-96.

5. Adelman M Adrizzo-Harris D. Management of nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med. 2018; 24(3): 212-219.

6. Griffith et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4): 367 – 416.

7. Song T et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug resistant tuberculosis. EBioMedicine. 2015; 9(2): 1627-33.

8. Villa G Di Maggio P De Gaudio A Novelli A Antoniotti R Fiaccadori E Adembri C. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/ pharmacodynamics: a systematic review. Crit Care. 2016; 20(1):374-80.

9. Stalker D Jungbluth G. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003; 42(13):1129-40.

10. Garrabou G et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers. Antimicrob Agents Chemother. 2017; 61(9): 542-47.

11. Santini A Ronchi D Garbellini M Piga D Protti A. Linezolid induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes. Expert Opin Drug Saf. 2017; 16(7): 833-43.

12. Milosevic T et al. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinally relevant concentrations in cultured human HL-60 promyelocytes and THP- 1 monocytes. Antimicrob Agents Chemother. 2018; 62(3): 599-617.

13. Douros A, Grabowski K, Stahlmann R. Drug-durg interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015; 11(12): 1849-59.

14. De Bus L et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010; 6(3): 322-6.

15. Im J Baek J Kwok H Lee J. Incidence and risk factors of linezolid-induced lactic acidosis. Int J Infect Dis. 2015; 31: 47-52.

16. Morata L et al. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother. 2016 Jun; 17(9): 1183-1187.

17. Mori N Kamimura J Kimura Y Hirose S Aoki Y Bito S. Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case–control studies of incidence and associated risk factors. Eur J Clin Pharmacol. 2018; 74(4): 405-411.

18. González-Del Castillo et al. Predictive score of haematological toxicity in patients treated with linezolid. Eur J Clin Microbiol Infect Dis. 2017; 36(8): 1511-1517.

19. Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int J Tuberc Lung Dis. 2016;20(12): 48-51.

20. Chang K Yew W Cheung S et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother. 2013; 57: 3445-49.

21. Carson J, Cerda J, Chae J, Hirano M, Maggiore P. Severe lactic acidosis associated with Linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy. 2007;27(5): 2771-74.

22. Fiaccadori E et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med. 2004; 32(12): 3437-42.